Siemens Medical Solutions USA, Inc.

Zoetis Services LLC

Zoetis LLC

Eli Lilly and Company

Threshold Pharmaceuticals, Inc.

Brian A Duclos

Wei Zhang

Joseph C Walsh

Hartmuth C Kolb

Umesh B Gangadharmath

Farhad Karimi

Qianwa Liang

Tieming Zhao

Henry Clifton Padgett

Dhanalakshmi Kasi

Zhiyong Gao

Thomas Lee Collier

Kai Chen

Vani P Mocharla

Bing Wang

Gang Chen

Richard Andrew Ewin

Timothy Allan Johnson

Paul D Johnson

Rajendran Vairagoundar

Graham M Kyne

Chunfang Xia

Edmund Lee Ellsworth

Eric Wang

Anjana Sinha

Peter J H Scott

Susan M K Sheehan

Derek James Sheehan

Donald James Skalitzky

Susan Mary Kult Sheehan

Susan M Sheehan

Robert M Yeh

Denis Billen

Michael Curtis

Richard M Goodwin

Andrea K Haber-Stuk

Peter Jh Scott

The present invention provides novel phenicol derivatives, their use for the treatment of infections in mammals, pharmaceutical compositions containing these novel compounds, and methods for the preparation of these compounds.

Phenicol antibacterials

The present invention provides novel cephalosporin derivatives of formula I, 

Cephalosporins useful as antibacterial agents

The present application discloses methods for identifying inhibitors with high binding-affinity for the carbonic anhydrase-IX (CA-IX) enzyme using click chemistry and uses the candidates thereof as positron emission tomography (PET) imaging agents.

Development of molecular imaging probes for carbonic anhydrase-IX using click chemistry

The present invention relates to novel radioactively labeled bioreducible tracers of Formula I useful for detecting hypoxic tumors or ischemic tissue in vivo. In one embodiment, the tracers consist of a 2-nitroimidazole moiety, a triazole, metabolically stable linker with pharmacokinetics enhancing substituents, and a radioisotope. The preferred in vivo imaging modality is positron emission tomography. 

Nitro-imidazole hypoxia imaging agent

Disclosed herein are novel radiolabeled nucleosides and methods for detecting cellular proliferation in a mammal, the method comprising administrating an effective amount of a radiolabeled nucleoside; the method comprising: a) administering to the mammal a diagnostically effective amount of the nucleoside to the mammal; b) allowing the nucleoside to distribute into the effective tissue; and c) imaging the tissue, wherein an increase in binding of the compound to tissue compared to a normal control level of binding indicates that the mammal is suffering from a disease involving cellular proliferation.

Nucleoside based proliferation imaging markers

Nitro-imidazole hypoxia imaging agents

Growing community of inventors

Kalamazoo, MI, United States of America

Brian A Duclos